Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib, Temozolomide, and Atezolizumab in Advanced Solid Tumors and Extensive-Stage SCLC
NCT03830918Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niraparib and temozolomide in solid tumor (advanced stage) and small cell lung cancer (SCLC) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Recommended Phase II Dose at 28 days and Progression-Free Survival up to 36 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
niraparibtemozolomide
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03830918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830918.